Table 2.
Associations between MT2A SNPs and breast cancer risk
| SNP genotype | Cases (%)/controls (%) | OR (95 % CI)a | p | OR (95 % CI)b | p |
|---|---|---|---|---|---|
| rs28366003 (SNP1) | |||||
| AA | 465 (87.1)/516 (92.8) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 66 (12.3)/40 (7.2) | 1.83 (1.21–2.77) | – | 1.92 (1.28–2.81) | |
| GG | 3 (0.6)/0 (0.0) | – | – | ||
| p trendc | <0.001 | <0.01 | |||
| AG or GG vs. AAd | 69 (12.9)/40 (7.2) | 1.91 (1.27–2.88) | <0.01 | 1.93 (1.29–2.89) | <0.02 |
| AG or AA vs. GGe | 531 (99.4)/556 (100) | – | – | – | – |
| rs1610216 (SNP2) | |||||
| AA | 408 (76.4)/402 (72.3) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 125 (23.4)/153 (27.5) | 0.80 (0.61–1.06) | 0.81 (0.63–1.09) | ||
| GG | 1 (0.2)/1 (0.2) | 0.98 (0.06–15.83) | 1.06 (0.09–16.72) | ||
| p trendc | 0.13 | 0.73 | |||
| AG or GG vs. AAd | 126 (23.6)/154 (27.7) | 0.81 (0.61–1.06) | 0.12 | 0.82 (0.64–1.11) | 0.24 |
| AG or AA vs. GGe | 533 (99.8)/555 (99.8) | 1.04 (0.06–16.69) | 0.98 | 0.97 (0.07–15.41) | 0.87 |
| rs10636 (SNP3) | |||||
| GG | 305 (57.1)/280 (50.3) | 1.00 (reference) | 1.00 (reference) | ||
| GC | 205 (38.4)/253 (45.5) | 0.74 (0.58–0.95) | 0.69 (0.52–0.94) | ||
| CC | 24 (4.5)/23 (4.2) | 0.96 (0.53–1.74) | 0.91 (0.64–1.71) | ||
| p trendc | 0.07 | 0.17 | |||
| CG or CC vs. GGd | 510 (95.5)/504 (90.6) | 0.76 (0.60–0.97) | 0.02 | 0.73 (0.57–0.96) | 0.06 |
| CG or GG vs. CCe | 229 (42.9)/301 (54.1) | 1.09 (0.61–1.96) | 0.07 | 1.11 (0.64–2.03) | 0.94 |
aCrude
bAdjusted for age, family history, smoking status, BMI, menarche, parity, menopausal status and use of contraceptive and menopausal hormones
cTesting additive genetic model (Cochran–Armitage test for trend)
dTesting dominant genetic model
eTesting recessive genetic model